Assessment of study quality
The validity of the studies was assessed using the following criteria: level of allocation concealment (graded A if adequate, B if unclear and C if inadequate); blinding; losses to follow-up; and whether a sample size was calculated a priori (see Other Publications of Related Interest no.1). The quality of the studies was assessed independently.
Data extraction
Two reviewers independently extracted the following data onto a standardised form: anaesthetic technique, study population, prehydration, uterine displacement and definition of maternal hypotension. Any discrepancies were resolved by discussion or with the aid of a third reviewer. Where necessary, the primary author was contacted for clarification of the data. In RCTs with more than one ephedrine treatment arm, the data were combined from each treatment arm for dichotomous outcomes (hypotension, hypertension, nausea and/or vomiting, and Apgar scores). For continuous outcomes (umbilical artery pH and standard base excess), the greatest ephedrine dose treatment arm was used if it was not possible to combine the data from all the ephedrine treatment arms.
Methods of synthesis
How were the studies combined?
The random-effects model of DerSimonian and Laird (see Other Publications of Related Interest no.2) was used to combine the data from continuous and dichotomous outcomes. The pooled relative risks (RRs) and 95% confidence intervals (CIs) were calculated for the dichotomous data. The continuous data were pooled using the weighted mean difference method and the 95% CIs were calculated. The number-needed-to-treat to prevent maternal hypotension was calculated using a baseline risk of 80%.
Publication bias was assessed using a funnel plot for the results on hypotension.
How were differences between studies investigated?
Statistical heterogeneity was assessed using the Q statistic, taking a p-value of less than 0.10 to indicate heterogeneity. Where heterogeneity was found, those studies considered to be the major contributors were evaluated. Sensitivity analyses were performed for hypotension. These assessed the influence of concealment of allocation (adequate versus unclear or inadequate), blinding (double-versus single-blinding) and intervention type (ephedrine given before hypotension versus ephedrine given when a small decrease in arterial pressure was detected).
Results of the review
Fourteen RCTs (641 women) were included.
Ephedrine was given before hypotension developed in 13 of the 14 RCTs.
Allocation concealment was adequate (grade A) in 4 RCTs and unclear (grade B) in 9 RCTs. It could not be clarified whether one trial was randomised. Seven RCTs were double-blinded, 4 were single-blinded and 3 were not blinded. Three RCTs provided details about withdrawals. Sample size calculations had been performed in 3 RCTs.
There was a wide variation in the ephedrine regimens used in the studies.
Maternal outcomes.
Hypotension (12 RCTs, 571 women): significantly fewer women experienced hypotension with ephedrine, compared with control (RR 0.73, 95%: CI 0.63, 0.86) . There was no evidence of statistical heterogeneity (P=0.24). The numberneeded-to-treat, assuming a baseline risk of 80%, was 4.6 (95% CI: 3.4, 8.9).
The overall effect was similar after excluding one RCT with uncertainty regarding the method of randomisation (RR 0.74, 95% CI: 0.65, 0.85), and was unchanged (RR 0.73, 95% CI: 0.61, 0.86) after excluding one RCT in which ephedrine was not given unless the arterial blood-pressure decreased to below baseline. The results were similar for the 4 RCTs with adequate allocation concealment (RR 0.69, 95% CI: 0.58, 0.83) and for the 7 RCTs with unclear allocation concealment (RR 0.76, 95% CI: 0.59, 0.99); in both cases there was no evidence of heterogeneity (p=0.56
